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modeled for a time horizon of 35-40 years or for a lifetime to demonstrate cost 
effectiveness. CONCLUSIONS: This analysis shows the range, variability, and 
methods used for calculation of ICER values for these high budget impact drugs 
and provides lessons for executives and policy makers.  
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OBJECTIVES: Health economics research is in its infancy in India. This 
systematic literature review aimed to identify, evaluate, and characterize  
the variety, quality, and intent of the health economics and outcomes studies 
being conducted in India. METHODS: Studies published in English language 
between 1999 and 2012 were retrieved from Embase and PubMed databases using 
relevant search strategies. Two researchers independently reviewed studies  
as per Cochrane methodology; information on type of research and outcomes 
were extracted. Quality of reporting was assessed for model-based health 
economic studies using a published 100-point Quality of Health Studies (QHES) 
instrument. Subjective assessment was used for the remaining studies. 
RESULTS: Of 546 studies screened, 132 studies were included in the review. The 
broad study categories were cost-effectiveness analyses ([CEA], 54 studies), cost 
analyses (19 studies), and burden of illness (18 studies). The outcomes evaluated 
in cost studies were direct and indirect costs, and incremental cost-effectiveness 
ratio (ICER), quality-adjusted life years (QALYs), and disability-adjusted life years 
(DALYs). Most studies were conducted from societal perspective. Direct medical 
costs assessed cost of medicines, monitoring costs, consultation and hospital 
charges along with non-medical costs (travel and food for patients and c 
are-givers). Loss of productivity and loss of income of patients and care-givers 
were identified as components of indirect cost. Overall, 33 studies assessed QoL, 
and WHO Quality of Life-BREF (WHOQOL-BREF) was the most commonly  
used instrument in these studies. Quality assessment for modeling studies 
showed that most studies were of high quality (mean [range] QHES score to be 
75.5 [34-93]). CONCLUSIONS: This review identified various patterns of health 
economic studies in India. Majority of the CEA studies conducted in recent years 
were of high quality. Despite this, utilization of health care resources is 
inappropriate and economic evaluation needs relevance to the context of health 
care in India.  
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OBJECTIVES: Economic evaluations of health technologies have long relied on 
one-way sensitivity analysis (SA) to examine the impact of parameter 
uncertainty on modeling outcomes. Traditionally, this impact has been 
measured and ranked based on absolute changes in the incremental cost-
effectiveness ratio (ICER) across plausible parameter values and presented in a 
tornado diagram. This format does not adequately identify or prioritize 
parameters where the range of uncertainty causes the ICER to change quadrants 
in the cost-effectiveness (CE) plane. However, these quadrant changes, which 
represent fundamental changes to the CE conclusion, are arguably more 
meaningful than changes in the ICER within a quadrant. This research illustrates 
a novel approach to presenting one-way SA results that focuses on identifying 
parameters with the greatest potential to change the overall CE conclusion 
rather than narrowly focusing on changes to the ICER. METHODS: We developed 
a comprehensive algorithm for ranking the parameters varied in a one-way SA. 
Broadly, we first prioritize parameters with the potential to qualitatively change 
the CE conclusion and then rank parameters based on quantitative changes to 
modeling outcomes. Changes to the CE conclusion are identified based on 
quadrant changes in the CE plane, and parameters are categorized as having the 
potential to change the conclusion both positively and negatively, only 
positively, only negatively, or not at all. Within these categories, a secondary 
ranking based on costs and health outcomes is used. Furthermore, visualization 
techniques anchored in the CE plane help assess whether conclusion changes 
are due primarily to changes in health, changes in costs, or both. RESULTS: This 
research demonstrates that the conclusions-based ranking algorithm works in 
more general settings than the traditional tornado diagram format. 
CONCLUSIONS: The conclusions-based approach is a powerful method that 
provides a more complete picture of the impact of parameter uncertainty in 
economic evaluations.  
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OBJECTIVES: Acute Medical Units (AMUs) identify individuals requiring in-
patient care and those who can be discharged. However, readmission rates for 
older people in the year following AMU discharge are high. We aimed to identify 
patient-based health and social–care costs of a cohort of older (70+) people 
discharged home from AMU within 72 hours. METHODS: Although resource-use 
data from social and health care sectors in England is available electronically, 
there is little systems-linkage so data were obtained from each sector separately. 
Hospitalisation and social care data were collected retrospectively for 644 
patients for three months post-AMU discharge using patient administration 
systems. In a subset (n=456), further approvals were gained for general practices, 
ambulance services, intermediate and mental health care. Of 118 general 
practices serving our cohort, data were obtained from 48 (250/456 participants). 
Seventeen were not covered by our approvals, and, despite an expert and 
dedicated team, 53 declined access or did not respond. RESULTS: We obtained 
data on hospitalisations for all participants, and “full” costs for 250 participants. 
Mean (95% CI, median, range) total cost for this subgroup was £2006 (1642-2470, 
0, 0-23612). Secondary care constituted 76.2% costs. Contribution from  
other sectors was: primary care (10.9%), ambulance service (0.7%), intermediate 
care (0.1%), mental health care (2.1%) and social care (10.0%) The top 10% 
participants accounted for 50% of overall cost. CONCLUSIONS: This study was 
resource-intensive due to: complex approvals and access requirements; 
geographical dispersion of participants and data sources; different recording 
systems; varying data quality; different care definitions across geographical 
sites; with manual data extraction often required. Care of older people is 
generally moving from secondary care to primary health care and social care, so 
the costs of other sectors will increase in the future. There is clearly a need to 
improve access and system interoperability and streamline methods for 
obtaining these costs.  
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OBJECTIVES: To validate a theoretical method, using a case study of efficiency 
frontier analysis for HIV/AIDS prevention and treatment, for quantifying lower 
and upper limits of the ICER configurated as a slope of the connected lines on  
the efficiency frontier, whose research poster in theory was presented at the 
ISPOR Dublin 2007. METHODS: A validation study was conducted based on the 
evidence published on the Journal of Medical Economics as one of the first 
studies that identified cost-effectiveness variation in efficient frontiers for 
HIV/AIDS prevention and treatment documented in the database, Cost-
Effectiveness Analysis Registry, at Tufts Medical Center in 2002-2007. RESULTS: 
Recognizing that there are two types of efficiency frontier represented with  
a monotonically increasing function of QALY on the Y-axis and Cost on the X-
axis, and also each efficiency frontier is formulated by two regression models: 
log and square-root models, two types of the mathematical formulae of 
derivatives were obtained according to each regression model. The formula of 
derivatives can provide the slope of the tangent on the efficiency frontier curve, 
given an arbitrary value of cost (or QALY). Therefore, we developed the formula 
that can provide lower and upper slopes of the two tangents, given an arbitrary 
ICER slope which is represented by connecting two points on the efficiency 
frontier curve. The examples of calculations conducted were graphically 
illustrated according to each regression model. CONCLUSIONS: Through this 
validation study, we can confirm that an application of our method is 
theoretically and practically feasible to estimate the lower and upper limits of an 
ICER arbitrarily given on the efficiency frontier curve. This approach will provide 
us with more useful information on the question how we could interpret and 
justify the high value of ICER of new technologies such as molecular-targeted 
drugs.  
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OBJECTIVES: Reimbursement to beneficiaries and cost-effectiveness analyses 
depend on the availability of estimates of billed-charge amounts. In the United 
States, no single data source is universally accepted; rather, several vendors 
compile distributions of billed charges. Studies use these estimates 
interchangeably and there is no preferred metric for characterizing differences in 
conducting comparisons. Nonetheless, the conventional wisdom suggests that 
Medicare data tend to underestimate means and other values relative to 
commercial data. This paper investigates the statistical properties of three 
metrics used to characterize relative differences between two sources of values. 
For these metrics, the difference between the tested and reference values is the 
numerator; the denominators are the tested value (Metric #1), the reference 
value (#2), or the average of the two (#3). METHODS: Each metric is described; 
mathematical proofs and simulations demonstrate the types of bias that can be 
introduced. RESULTS: Two simulations of constructed distributions with 
identical means, one with small value differences and the other with large value 
differences, demonstrate that Metrics #1 and #2 would result in opposite 
inferences. Proofs demonstrate that the expected values of Metrics #1, #2, and #3 
respectively, are negative, positive, and zero. The head to head comparison of 
two billed charge benchmarks finds bias present across all three averages 
(simple, weighted by claim count, and weighted by claim dollars), although it is 
most pervasive for the simple average. The sign of the average of Metric #1 is 
consistently negative, while that for Metric #2 is positive and Metric #3 varies. 
CONCLUSIONS: When many observations are aggregated to generate an overall 
average, the choice of metric affects results, often to the point where the choice 
of one methodology or another can generate diametrically opposite conclusions. 
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Results demonstrate the importance of sensitivity analyses and thoughtful 
consideration of the metric and benchmark selection.  
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OBJECTIVES: Lupus nephritis (LN) is a severe complication of systemic lupus 
erythematosus (SLE). While LN has no designated ICD-9 code, various 
approaches have been used to identify patients in administrative data. The 
objective was to compare health resource utilization of LN patients using 
different algorithms in a single data source. METHODS: This study used the 
Impact Database, a commercial insurance claims database. SLE patients were 
identified using ICD-9 code 710.0 from ≥2 outpatient or 1 inpatient claims from 
01/2004 to 06/2011. SLE patients with LN were further identified under four 
different algorithms: (A) ≥1 renal diagnosis, (B) ≥2 renal diagnoses, (C) ≥3 renal 
diagnoses, and (D) ≥3 renal diagnoses plus ≥3 nephrologist visits. Health resource 
utilization and expenditure of outpatient/emergency department (ED) visits, 
hospitalizations, and prescriptions were examined for 12 months post index date 
of first renal diagnosis. RESULTS: A total of 93,957 patients were diagnosed with 
SLE. Among them, 24,357, 11,054, 8,895, and 6,307 cases had LN using algorithms 
A-D. LN cases identified by algorithms A-D had similar mean age (48.3, 46.7, 46.3, 
and 45.7 years) and gender distribution (85.2, 83.1, 82.7, and 81.8% females). LN 
patients from different algorithms also had similar annual frequency of 
outpatient visit (35.9, 41.0, 41.1, and 42.1), ED visit (1.4, 1.4, 1.4, and 1.5), 
hospitalization (0.8, 0.9, 0.9, and 0.9), and prescription (6.8, 7.3, 7.2, and 7.4). The 
annual medical expenditures were $33,176, $36,974, $36,241, and $38,883 for 
algorithms A, B, C, and D, respectively. CONCLUSIONS: Our results support that 
when studying health resource utilization, the results do not differ significantly 
based on the number of renal diagnoses codes. There is a difference in outcomes 
when requiring number of patients plus specialty subtype; however, in the case 
where specialty information is either unavailable or unreliable, using algorithms 
A-C proved equally reliable in an administrative claims database.  
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OBJECTIVES: Compare traditional and zero-inflated gamma regression models 
for the analysis of health care costs in an administrative claims database. 
Gamma regression models are widely used for the analysis of health care cost 
data and are appropriate for analyzing mean costs within patients incurring >$0. 
However, little research is available for the appropriateness of gamma regression 
on data with a high proportion of $0 costs. METHODS: This study used the 
HealthCore Integrated Research Environment to analyze hospitalization costs 
within 3,049 bipolar patients initiating antipsychotic medications (Drug X=2,398 
patients; Drug Y=651 patients). Results of a traditional gamma model and a zero-
inflated gamma model were compared. The zero-inflated model used SAS 
procedure NLMIXED to perform logistic regression modelling the probability of 
having a hospitalization, gamma regression modelling mean costs within 
patients having a hospitalization, and combining the two models to analyze 
differences in overall mean cost. RESULTS: There were 18.3% Drug X patients 
with an inpatient hospitalization, compared with 12.1% of Drug Y. Mean costs 
were higher for Drug X within only patients having an event ($17,721 vs. $11,425) 
and including patients with no event ($3,237 vs. $1,387). Gamma regression 
found the difference in the overall population to be significant (mean-
diff=$1,850, CI=[$1,463;$2,152], p<0.0001). The zero-inflated gamma regression 
model showed similar results (mean-diff=$1,850, CI=[$1,237;$2,464], p<0.0001). 
Consistent results between the models were also seen when adjusting for 
patient demographics, comorbidities, and prior medications: traditional gamma 
model (mean-diff=$2,173, CI=[$716;$1,297], p<0.0001), zero-inflated gamma 
model (mean-diff=$2,448, CI=[$597;$1,670], p<0.0001). CONCLUSIONS: When 
analyzing health care cost data containing >80% $0 costs, little difference was 
seen between traditional gamma regression and zero-inflated gamma regression 
models. The zero-inflated model uses complex coding, and requires advanced 
knowledge of statistical methods and SAS programming. Within data containing 
a large proportion of $0 costs, traditional gamma regression is appropriate for 
analyzing differences in mean costs.  
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OBJECTIVES: 1) To study the relative performance of various graphical and 
analytical diagnostics used to assess the assumption of an underlying gamma 
distribution for a commonly used model in the examination of health care 
expenditures (GLMAGALL – a generalized linear model assuming a gamma 
distribution with a log link relating the mean costs to a corresponding set of 
predictors), and 2) To investigate each diagnostic’s ability to discriminate 
between various assumed distributions (e.g., gamma versus log-normal) that 
may be potentially used in health care cost analysis. METHODS: Data sets will be 
created via Monte Carlo simulation of gamma (varying the shape and scale 
parameters) and other distributions, as well as, by altering the values for a small 
set of predictors. The results of the diagnostic study will be illustrated in a 
graphical and/or tabular format. RESULTS: Graphical diagnostics afford the 
analyst the ability to see subtle or dramatic departures from the model’s 
distributional assumptions that might not be as obvious by using an analytical 
model that provides a single summary statistic. CONCLUSIONS: The 
performance of a diagnostic procedure to assess the presence of a gamma 
distribution in a cost model or its ability to discriminate between one 
distribution and another is important; however, other factors must be 
considered before an analyst makes his or her final choice. The ease of executing 
the technique, its relative clarity of interpretation, and availability in a software 
package (without having to resort to extensive programming beyond what is 
provided by a standard statistical package) must all be considered to ensure that 
model adequacy testing may be performed readily so that the choice of a 
distribution for an expenditure model may be considered sound.  
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OBJECTIVES: To develop algorithms identifying if metastatic colorectal cancer 
(mCRC) patients were tested for KRAS (a tumor biomarker of EGFR-inhibitor 
response) using text documents (e.g., physician progress notes) within electronic 
medical records (EMR). METHODS: The sample consisted of 1,385 mCRC patients 
from the ACORN Data Warehouse. 300 patients were randomly selected for chart 
review and randomly assigned to training (n=150), validation (n=50), or testing 
datasets (n=100); 1,085 patients comprised a scoring dataset. Counts of terms in 
text-based content of patient EMRs were used to develop models predicting 
KRAS testing status. RESULTS: Several models were used to predict KRAS testing 
in the training sample. Decision tree (DT), random forest (RF), and adaptive 
boosting (AB) models performed best when applied to validation data not used in 
the earlier model development process. RF outperformed DT and AB. RF was the 
only model to produce a kappa ≥ 0.80 (within rounding) for both the validation 
and testing datasets. It also produced the highest kappa in the testing dataset 
(kappa=0.7994), as well as fewer false negatives. RF was used to score the 
remaining 1,085 patients. All patients predicted “tested” and a random sample of 
patients predicted “not tested” underwent chart review. The model correctly 
predicted KRAS “tested” 482/500 times (PPV=96.4%) and “not tested” 196/200 
times (NPV=98.0%), kappa= 0.970. CONCLUSIONS: Text mining yielded highly 
accurate classification of KRAS testing status among mCRC patients. Review of 
the small number of misclassified cases of KRAS testing identified ways to 
improve the model’s accuracy. These results may inform future research and 
reduce the need for labor-intensive and costly full chart review by human 
coders.  
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OBSERVATIONAL STUDIES OF COMPARATIVE EFFECTIVENESS  
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OBJECTIVES: To be able to identify observational studies of good enough quality 
for decision support by validating a set of screening questions to qualify studies 
likely to produce reasonably accurate and unbiased estimates of comparative 
effectiveness (CE). METHODS: An 11-item checklist was developed through 
literature review and consultation with experts from ISPOR, ISPE, payer groups, 
private sector and academia. Item content covers four quality domains: 
comparability of subjects, information about the exposure or intervention, 
outcome measurement, and statistical analysis, which are metrics similar to 
those used in assessing observational study quality for systematic reviews. 
Checklist items were tested using studies of drugs, medical devices and medical 
procedures. We focused on research quality, not applicability to any decision. A 
fundamental challenge was to find a gold standard against which to test 
checklist items. 113 volunteers from 5 continents each rated >3 articles (N=280 
assessments) from three validation sets of studies that 1) had quality 
assessments published in systematic reviews; 2) were assessed for quality by one 
of nine advisors from academic and payer groups; or 3) were assessed for quality 
by two of the nine advisors. RESULTS: Expert reviews uncovered an unsettling 
lack of agreement about what “good” looks like, especially in situations that 
lacked context, with 52% concordance (5 experts, 23 assessments.) The single 
best performing checklist item, data quality for the primary outcome(s), scored 
>= 0.67 for positive predictive value in 4 of 6 samples and > = 0.67 for negative 
predictive values in all 6 samples. Another high scoring question, sensitivity 
analyses, had a positive predictive value >= 0.69 for in all 6 samples. 
CONCLUSIONS: This quantitative study shows that many content items 
recommended by experts do not consistently distinguish high quality 
observational CE studies.  
 
PRM52  
ASSOCIATION BETWEEN CARDIOVASCULAR BIOMARKERS LEVELS AND 
CIGARETTE SMOKING AMONG CURRENT SMOKERS, PAST SMOKERS AND NON 
SMOKERS USING NHANES 2007-2010  
Saxena K1, Liang Q2, Muhammad-Kah R2, Sarkar M2 
1Virginia Commonwealth University, Richmond, VA, USA, 2Altria Client Services Inc., Richmond, 
VA, USA  
